- Home
- MYGN vs BMEZ Comparison
MYGN vs BMEZ Comparison
Compare MYGN & BMEZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- BMEZ
- Stock Information
- Founded
- MYGN 1991
- BMEZ N/A
- Country
- MYGN United States
- BMEZ United States
- Employees
- MYGN N/A
- BMEZ N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- BMEZ Trusts Except Educational Religious and Charitable
- Sector
- MYGN Health Care
- BMEZ Finance
- Exchange
- MYGN Nasdaq
- BMEZ Nasdaq
- Market Cap
- MYGN 2.0B
- BMEZ 1.7B
- IPO Year
- MYGN 1995
- BMEZ N/A
- Fundamental
- Price
- MYGN $13.69
- BMEZ $15.06
- Analyst Decision
- MYGN Hold
- BMEZ
- Analyst Count
- MYGN 12
- BMEZ 0
- Target Price
- MYGN $23.92
- BMEZ N/A
- AVG Volume (30 Days)
- MYGN 904.0K
- BMEZ 391.3K
- Earning Date
- MYGN 11-07-2024
- BMEZ 01-01-0001
- Dividend Yield
- MYGN N/A
- BMEZ 8.71%
- EPS Growth
- MYGN N/A
- BMEZ N/A
- EPS
- MYGN N/A
- BMEZ 0.54
- Revenue
- MYGN $823,600,000.00
- BMEZ N/A
- Revenue This Year
- MYGN $13.82
- BMEZ N/A
- Revenue Next Year
- MYGN $4.59
- BMEZ N/A
- P/E Ratio
- MYGN N/A
- BMEZ $30.17
- Revenue Growth
- MYGN 12.15
- BMEZ N/A
- 52 Week Low
- MYGN $13.81
- BMEZ $12.93
- 52 Week High
- MYGN $29.30
- BMEZ $16.95
- Technical
- Relative Strength Index (RSI)
- MYGN 26.49
- BMEZ 38.88
- Support Level
- MYGN $13.92
- BMEZ $15.34
- Resistance Level
- MYGN $15.44
- BMEZ $15.86
- Average True Range (ATR)
- MYGN 0.79
- BMEZ 0.21
- MACD
- MYGN 0.03
- BMEZ -0.05
- Stochastic Oscillator
- MYGN 3.06
- BMEZ 6.68
About MYGN Myriad Genetics Inc.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
About BMEZ BlackRock Health Sciences Term Trust of Beneficial Interest
BlackRock Health Sciences Trust II is a closed-ended management investment company. The investment objective is to provide total return through a combination of current income and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities of energy and natural resources companies and equity derivatives with exposure to the energy and natural resources industry.